Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

Diane Newman gives insight into problems that arise when deflating the balloon of the Foley (indwelling) urinary catheter. She provides helpful tips, such as how to remove blockages that may prevent ...

EAU 2018 Press EAU 2018: Analysis shows influential US prostate study not representative of real-world patients EAU 2018: Quality of Life of Spouses Living with Men Undergoing Androgen Deprivation ...

AUA 2025 trial protocol of CORE-008, intravesical cretostimogene grenadenorepvec, non-muscle invasive bladder cancer (NMIBC), RB-E2F alterations.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Wolfgang P. Fendler, MD, discussing PSMA-PET and PROMISE re-defining stage and risk in ...

Marco Moschini joins Sam Chang in a discussion on highlighting a European Urology Oncology publication that sought to review the available literature systematically focused on incidence, diagnosis, ...

Read the Full Video Transcript Diane Newman: Welcome to UroToday's Bladder Health Center of Excellence. I am Diane Newman, the center's Editor, and Adjunct Professor of Urology and Surgery at the ...

WCE 2019: Ambulatory Percutaneous Nephrolithotomy in Free - Standing Surgery Center: Outcomes of the First 550 Cases WCE 2019: Investigating the Role of Smaller Tract Percutaneous Nephrolithotomy in ...

ASCO GU 2025, prostate cancer, Gut Health and Prostate Cancer, The Influence of a Specific Phytochemical-Rich Food Capsule plus or Minus a Probiotic/prebiotic Blend on Symptoms and progression of ...

Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 ...

Barcelona, Spain (UroToday.com) Rucaparib is a PARP inhibitor and has shown antitumor activity in patients with mCRPC and a deleterious DNA damage repair-deficient gene alteration. Initial results ...

Anticholinergic medications have long been mainstays of overactive bladder (OAB) treatment. Oxybutynin, a first-generation anticholinergic, still accounts for more than half of all OAB medication ...